Anti-Angiogenic Agents Combined with Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Sung, H.; Ferlay, J.; Siegel, RL. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin., 2021, 71(3), 209-249.

Herbst, R.S.; Morgensztern, D.; Boshoff, C. The biology and management of non-small cell lung cancer. Nature., 2018, 553(7689), 446-454.
[http://dx.doi.org/10.1038/nature25183] [PMID: 29364287]

Siegel, RL; Miller, KD Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48.

Arbour, K.C.; Riely, G.J. Systemic therapy for locally advanced and metastatic non–small cell lung cancer. JAMA, 2019, 322(8), 764-774.
[http://dx.doi.org/10.1001/jama.2019.11058] [PMID: 31454018]

Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 2018, 68(6), 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]

Doroshow, D.B.; Sanmamed, M.F.; Hastings, K.; Politi, K.; Rimm, D.L.; Chen, L.; Melero, I.; Schalper, K.A.; Herbst, R.S. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes. Clin. Cancer Res., 2019, 25(15), 4592-4602.
[http://dx.doi.org/10.1158/1078-0432.CCR-18-1538] [PMID: 30824587]

Lim, S.M.; Hong, M.H.; Kim, H.R. Immunotherapy for non-small cell lung cancer: Current landscape and future perspectives. Immune Netw., 2020, 20(1), e10.
[http://dx.doi.org/10.4110/in.2020.20.e10] [PMID: 32158598]

Mok, T.S.K.; Wu, Y.L.; Kudaba, I.; Kowalski, D.M.; Cho, B.C.; Turna, H.Z.; Castro, G., Jr; Srimuninnimit, V.; Laktionov, K.K.; Bondarenko, I.; Kubota, K.; Lubiniecki, G.M.; Zhang, J.; Kush, D.; Lopes, G.; Adamchuk, G.; Ahn, M-J.; Alexandru, A.; Altundag, O.; Alyasova, A.; Andrusenko, O.; Aoe, K.; Araujo, A.; Aren, O.; Arrieta Rodriguez, O.; Ativitavas, T.; Avendano, O.; Barata, F.; Barrios, C.H.; Beato, C.; Bergstrom, P.; Betticher, D.; Bolotina, L.; Bondarenko, I.; Botha, M.; Buddu, S.; Caglevic, C.; Cardona, A.; Castro, G., Jr; Castro, H.; Cay Senler, F.; Cerny, C.A.S.; Cesas, A.; Chan, G-C.; Chang, J.; Chen, G.; Chen, X.; Cheng, S.; Cheng, Y.; Cherciu, N.; Chiu, C-H.; Cho, B.C.; Cicenas, S.; Ciurescu, D.; Cohen, G.; Costa, M.A.; Danchaivijitr, P.; De Angelis, F.; de Azevedo, S.J.; Dediu, M.; Deliverski, T.; De Marchi, P.R.M.; de The Bustamante Valles, F.; Ding, Z.; Doganov, B.; Dreosti, L.; Duarte, R.; Edusma-Dy, R.; Emelyanov, S.; Erman, M.; Fan, Y.; Fein, L.; Feng, J.; Fenton, D.; Fernandes, G.; Ferreira, C.; Franke, F.A.; Freitas, H.; Fujisaka, Y.; Galindo, H.; Galvez, C.; Ganea, D.; Gil, N.; Girotto, G.; Goker, E.; Goksel, T.; Gomez Aubin, G.; Gomez Wolff, L.; Griph, H.; Gumus, M.; Hall, J.; Hart, G.; Havel, L.; He, J.; He, Y.; Hernandez Hernandez, C.; Hespanhol, V.; Hirashima, T.; Ho, C.M.J.; Horiike, A.; Hosomi, Y.; Hotta, K.; Hou, M.; How, S.H.; Hsia, T-C.; Hu, Y.; Ichiki, M.; Imamura, F.; Ivashchuk, O.; Iwamoto, Y.; Jaal, J.; Jassem, J.; Jordaan, C.; Juergens, R.A.; Kaen, D.; Kalinka-Warzocha, E.; Karaseva, N.; Karaszewska, B.; Kazarnowicz, A.; Kasahara, K.; Katakami, N.; Kato, T.; Kawaguchi, T.; Kim, J.H.; Kishi, K.; Kolek, V.; Koleva, M.; Kolman, P.; Koubkova, L.; Kowalyszyn, R.; Kowalski, D.; Koynov, K.; Ksienski, D.; Kubota, K.; Kudaba, I.; Kurata, T.; Kuusk, G.; Kuzina, L.; Laczo, I.; Ladrera, G.E.I.; Laktionov, K.; Landers, G.; Lazarev, S.; Lerzo, G.; Lesniewski Kmak, K.; Li, W.; Liam, C.K.; Lifirenko, I.; Lipatov, O.; Liu, X.; Liu, Z.; Lo, S.H.; Lopes, V.; Lopez, K.; Lu, S.; Martinengo, G.; Mas, L.; Matrosova, M.; Micheva, R.; Milanova, Z.; Miron, L.; Mok, T.; Molina, M.; Murakami, S.; Nakahara, Y.; Nguyen, T.Q.; Nishimura, T.; Ochsenbein, A.; Ohira, T.; Ohman, R.; Ong, C.K.; Ostoros, G.; Ouyang, X.; Ovchinnikova, E.; Ozyilkan, O.; Petruzelka, L.; Pham, X.D.; Picon, P.; Piko, B.; Poltoratsky, A.; Ponomarova, O.; Popelkova, P.; Purkalne, G.; Qin, S.; Ramlau, R.; Rappaport, B.; Rey, F.; Richardet, E.; Roubec, J.; Ruff, P.; Rusyn, A.; Saka, H.; Salas, J.; Sandoval, M.; Santos, L.; Sawa, T.; Seetalarom, K.; Seker, M.; Seki, N.; Seolwane, F.; Shepherd, L.; Shevnya, S.; Shimada, A.K.; Shparyk, Y.; Sinielnikov, I.; Sirbu, D.; Smaletz, O.; Soares, J.P.H.; Sookprasert, A.; Speranza, G.; Srimuninnimit, V.; Sriuranpong, V.; Stara, Z.; Su, W-C.; Sugawara, S.; Szpak, W.; Takahashi, K.; Takigawa, N.; Tanaka, H.; Tan Chun Bing, J.; Tang, Q.; Taranov, P.; Tejada, H.; Tho, L.M.; Torii, Y.; Trukhyn, D.; Turdean, M.; Turna, H.; Ursol, G.; Vanasek, J.; Varela, M.; Vallejo, M.; Vera, L.; Victorino, A-P.; Vlasek, T.; Vynnychenko, I.; Wang, B.; Wang, J.; Wang, K.; Wu, Y.; Yamada, K.; Yang, C-H.; Yokoyama, T.; Yokoyama, T.; Yoshioka, H.; Yumuk, F.; Zambrano, A.; Zarba, J.J.; Zarubenkov, O.; Zemaitis, M.; Zhang, L.; Zhang, L.; Zhang, X.; Zhao, J.; Zhou, C.; Zhou, J.; Zhou, Q.; Zippelius, A. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet, 2019, 393(10183), 1819-1830.
[http://dx.doi.org/10.1016/S0140-6736(18)32409-7] [PMID: 30955977]

Sezer, A.; Kilickap, S.; Gümüş, M.; Bondarenko, I.; Özgüroğlu, M.; Gogishvili, M.; Turk, H.M.; Cicin, I.; Bentsion, D.; Gladkov, O.; Clingan, P.; Sriuranpong, V.; Rizvi, N.; Gao, B.; Li, S.; Lee, S.; McGuire, K.; Chen, C.I.; Makharadze, T.; Paydas, S.; Nechaeva, M.; Seebach, F.; Weinreich, D.M.; Yancopoulos, G.D.; Gullo, G.; Lowy, I.; Rietschel, P. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet, 2021, 397(10274), 592-604.
[http://dx.doi.org/10.1016/S0140-6736(21)00228-2] [PMID: 33581821]

Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O’Brien, M.; Rao, S.; Hotta, K.; Leiby, M.A.; Lubiniecki, G.M.; Shentu, Y.; Rangwala, R.; Brahmer, J.R. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N. Engl. J. Med., 2016, 375(19), 1823-1833.
[http://dx.doi.org/10.1056/NEJMoa1606774] [PMID: 27718847]

Hellmann, M.D.; Paz-Ares, L.; Bernabe Caro, R.; Zurawski, B.; Kim, S.W.; Carcereny Costa, E.; Park, K.; Alexandru, A.; Lupinacci, L.; de la Mora Jimenez, E.; Sakai, H.; Albert, I.; Vergnenegre, A.; Peters, S.; Syrigos, K.; Barlesi, F.; Reck, M.; Borghaei, H.; Brahmer, J.R.; O’Byrne, K.J.; Geese, W.J.; Bhagavatheeswaran, P.; Rabindran, S.K.; Kasinathan, R.S.; Nathan, F.E.; Ramalingam, S.S. Nivolumab plus Ipilimumab in advanced non–small-cell lung cancer. N. Engl. J. Med., 2019, 381(21), 2020-2031.
[http://dx.doi.org/10.1056/NEJMoa1910231] [PMID: 31562796]

Herbst, R.S.; Giaccone, G.; de Marinis, F.; Reinmuth, N.; Vergnenegre, A.; Barrios, C.H.; Morise, M.; Felip, E.; Andric, Z.; Geater, S.; Özgüroğlu, M.; Zou, W.; Sandler, A.; Enquist, I.; Komatsubara, K.; Deng, Y.; Kuriki, H.; Wen, X.; McCleland, M.; Mocci, S.; Jassem, J.; Spigel, D.R. Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC. N. Engl. J. Med., 2020, 383(14), 1328-1339.
[http://dx.doi.org/10.1056/NEJMoa1917346] [PMID: 32997907]

Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; Cho, B.C.; Bourhaba, M.; Quantin, X.; Tokito, T.; Mekhail, T.; Planchard, D.; Kim, Y.C.; Karapetis, C.S.; Hiret, S.; Ostoros, G.; Kubota, K.; Gray, J.E.; Paz-Ares, L.; de Castro Carpeño, J.; Faivre-Finn, C.; Reck, M.; Vansteenkiste, J.; Spigel, D.R.; Wadsworth, C.; Melillo, G.; Taboada, M.; Dennis, P.A.; Özgüroğlu, M. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med., 2018, 379(24), 2342-2350.
[http://dx.doi.org/10.1056/NEJMoa1809697] [PMID: 30280658]

Reck, M.; Rodríguez-Abreu, D.; Robinson, A.G.; Hui, R.; Csőszi, T.; Fülöp, A.; Gottfried, M.; Peled, N.; Tafreshi, A.; Cuffe, S.; O´Brien, M.; Rao, S.; Hotta, K.; Vandormael, K.; Riccio, A.; Yang, J.; Pietanza, M.C.; Brahmer, J.R. Updated Analysis of KEYNOTE-024: Pembrolizumab versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. J. Clin. Oncol., 2019, 37(7), 537-546.
[http://dx.doi.org/10.1200/JCO.18.00149] [PMID: 30620668]

Lu, S.; Wang, J.; Cheng, Y.; Mok, T.; Chang, J.; Zhang, L.; Feng, J.; Tu, H.Y.; Wu, L.; Zhang, Y.; Luft, A.; Zhou, J.; Ma, Z.; Lu, Y.; Hu, C.; Shi, Y.; Ying, K.; Zhong, H.; Poddubskaya, E.; Soo, R.A.; Chia, Y.H.; Li, A.; Li, A.; Wu, Y.L. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078). Lung Cancer, 2021, 152, 7-14.
[http://dx.doi.org/10.1016/j.lungcan.2020.11.013] [PMID: 33321441]

Park, SE; Lee, SH; Ahn, JS; Ahn, MJ; Park, K; Sun, JM Increased response rates to salvage chemotherapy administered after PD-1/PD-L1 inhibitors in patients with non-small cell lung cancer. J Thorac Oncol., 2018, 13(1), 106-111.

Herbst, R.S.; Bendell, J.C.; Isambert, N.; Calvo, E.; Santana-Davila, R.; Cassier, P.; Perez-Gracia, J.L.; Yang, J.; Rege, J.; Ferry, D. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Am. Soc Clin Oncol., 2016, 32, 15.
[http://dx.doi.org/10.1200/JCO.2016.34.15_suppl.3056]

Rizvi, N.A.; Antonia, S.J.; Shepherd, F.A.; Chow, L.Q.; Goldman, J.; Shen, Y.; Chen, A.C.; Gettinger, S. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) maintenance as monotherapy or in combination with bevacizumab (BEV) for non-small cell lung cancer (NSCLC) previously treated with chemotherapy: Metastatic non-small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 2014, 90(5), S32.
[http://dx.doi.org/10.1016/j.ijrobp.2014.08.206]

Abdelazeem, B.; Abbas, K.S.; Labieb, F.; Arida, A.K.; El-Shahat, N.A.; Shehata, J.; Kandah, E.; Malik, B.; Akanbi, M.; Rafae, A.; Wahab, A.; Ehsan, H. The role of immunotherapy plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-small cell lung cancer: An updated systematic review and meta-analysis of randomized controlled trials. Expert Rev. Anticancer Ther., 2022, 22(10), 1127-1140.
[http://dx.doi.org/10.1080/14737140.2022.2116005] [PMID: 35993418]

Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; Rodríguez-Cid, J.; Wilson, J.; Sugawara, S.; Kato, T.; Lee, K.H.; Cheng, Y.; Novello, S.; Halmos, B.; Li, X.; Lubiniecki, G.M.; Piperdi, B.; Kowalski, D.M. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N. Engl. J. Med., 2018, 379(21), 2040-2051.
[http://dx.doi.org/10.1056/NEJMoa1810865] [PMID: 30280635]

Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; Cheng, S.Y.S.; Bischoff, H.G.; Peled, N.; Grossi, F.; Jennens, R.R.; Reck, M.; Hui, R.; Garon, E.B.; Boyer, M.; Rubio-Viqueira, B.; Novello, S.; Kurata, T.; Gray, J.E.; Vida, J.; Wei, Z.; Yang, J.; Raftopoulos, H.; Pietanza, M.C.; Garassino, M.C. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N. Engl. J. Med., 2018, 378(22), 2078-2092.
[http://dx.doi.org/10.1056/NEJMoa1801005] [PMID: 29658856]

Zondor, S.D.; Medina, P.J. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann. Pharmacother., 2004, 38(7-8), 1258-1264.
[http://dx.doi.org/10.1345/aph.1D470] [PMID: 15187215]

Tian, W.; Cao, C.; Shu, L.; Wu, F. Anti-Angiogenic therapy in the treatment of non-small cell lung cancer. OncoTargets Ther., 2020, 13, 12113-12129.
[http://dx.doi.org/10.2147/OTT.S276150] [PMID: 33262610]

Manegold, C.; Dingemans, A.C.; Gray, J.E.; Nakagawa, K.; Nicolson, M.; Peters, S.; Reck, M.; Wu, Y.L.; Brustugun, O.T.; Crinò, L. The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC. J. Thorac. Oncol., 2017, 12(2), 194-207.

Li, B.; Lalani, A.S.; Harding, T.C.; Luan, B.; Koprivnikar, K.; Huan Tu, G.; Prell, R.; VanRoey, M.J.; Simmons, A.D.; Jooss, K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin. Cancer Res., 2006, 12(22), 6808-6816.
[http://dx.doi.org/10.1158/1078-0432.CCR-06-1558] [PMID: 17121902]

Huang, Y.; Kim, B.Y.S.; Chan, C.K.; Hahn, S.M.; Weissman, I.L.; Jiang, W. Improving immune–vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol., 2018, 18(3), 195-203.
[http://dx.doi.org/10.1038/nri.2017.145] [PMID: 29332937]

Tian, L.; Goldstein, A.; Wang, H.; Ching Lo, H.; Sun Kim, I.; Welte, T.; Sheng, K.; Dobrolecki, L.E.; Zhang, X.; Putluri, N.; Phung, T.L.; Mani, S.A.; Stossi, F.; Sreekumar, A.; Mancini, M.A.; Decker, W.K.; Zong, C.; Lewis, M.T.; Zhang, X.H.F. Mutual regulation of tumour vessel normalization and immunostimulatory] reprogramming. Nature, 2017, 544(7649), 250-254.
[http://dx.doi.org/10.1038/nature21724] [PMID: 28371798]

Rini, B.I.; Plimack, E.R.; Stus, V.; Gafanov, R.; Hawkins, R.; Nosov, D.; Pouliot, F.; Alekseev, B.; Soulières, D.; Melichar, B.; Vynnychenko, I.; Kryzhanivska, A.; Bondarenko, I.; Azevedo, S.J.; Borchiellini, D.; Szczylik, C.; Markus, M.; McDermott, R.S.; Bedke, J.; Tartas, S.; Chang, Y.H.; Tamada, S.; Shou, Q.; Perini, R.F.; Chen, M.; Atkins, M.B.; Powles, T. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med., 2019, 380(12), 1116-1127.
[http://dx.doi.org/10.1056/NEJMoa1816714] [PMID: 30779529]

Liu, J.F.; Herold, C.; Gray, K.P.; Penson, R.T.; Horowitz, N.; Konstantinopoulos, P.A.; Castro, C.M.; Hill, S.J.; Curtis, J.; Luo, W.; Matulonis, U.A.; Cannistra, S.A.; Dizon, D.S. Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer. JAMA Oncol., 2019, 5(12), 1731-1738.
[http://dx.doi.org/10.1001/jamaoncol.2019.3343] [PMID: 31600397]

Herbst, R.S.; Arkenau, H.T.; Santana-Davila, R.; Calvo, E.; Paz-Ares, L.; Cassier, P.A.; Bendell, J.; Penel, N.; Krebs, M.G.; Martin-Liberal, J.; Isambert, N.; Soriano, A.; Wermke, M.; Cultrera, J.; Gao, L.; Widau, R.C.; Mi, G.; Jin, J.; Ferry, D.; Fuchs, C.S.; Petrylak, D.P.; Chau, I. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro- oesophageal cancer, or urothelial carcinomas (JVDF): A multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol., 2019, 20(8), 1109-1123.
[http://dx.doi.org/10.1016/S1470-2045(19)30458-9] [PMID: 31301962]

Chu, T; Zhong, R; Zhong, H; Zhang, B; Zhang, W; Shi, C; Qian, J; Zhang, Y; Chang, Q; Zhang, X Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC J Thorac Oncol., 2021, 16(4), 643-652.

Ren, S.; He, J.; Fang, Y.; Chen, G.; Ma, Z.; Chen, J.; Guo, R.; Lin, X.; Yao, Y.; Wu, G.; Wang, Q.; Zhou, C. MA13.01 camrelizumab plus apatinib in treatment-naive patients with advanced non-squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial. J. Thorac. Oncol., 2021, 16(10), S924.
[http://dx.doi.org/10.1016/j.jtho.2021.08.175]

Bang, YJ; Golan, T; Dahan, L; Fu, S; Moreno, V; Park, K; Geva, R; De Braud, F; Wainberg, ZA; Reck, M Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J. Cancer., 2020, 137(15 suppl), 272-284.

Zhou, N.; Jiang, M.; Li, T.; Zhu, J.; Liu, K.; Hou, H.; Zhang, X. Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study. Lung Cancer, 2021, 160, 111-117.
[http://dx.doi.org/10.1016/j.lungcan.2021.08.006] [PMID: 34482102]

Zhai, C.; Zhang, X.; Ren, L.; You, L.; Pan, Q.; Pan, H.; Han, W. The efficacy and safety of anlotinib combined with PD-1 antibody for third-line or further-line treatment of patients with advanced non-small-cell lung cancer. Front. Oncol., 2021, 10, 619010.
[http://dx.doi.org/10.3389/fonc.2020.619010] [PMID: 33680942]

Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]

Slim, K.; Nini, E.; Forestier, D.; Kwiatkowski, F.; Panis, Y.; Chipponi, J. Methodological index for non-randomized studies (MINORS): Development and validation of a new instrument. ANZ J. Surg., 2003, 73(9), 712-716.
[http://dx.doi.org/10.1046/j.1445-2197.2003.02748.x] [PMID: 12956787]

Wang, P.; Fang, X.; Yin, T.; Tian, H.; Yu, J.; Teng, F. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non–Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study. Front. Oncol., 2021, 11, 628124.
[http://dx.doi.org/10.3389/fonc.2021.628124] [PMID: 33791214]

Chen, Y.; Li, X.; Liu, G.; Chen, S.; Xu, M.; Song, L.; Wang, Y. ctDNA concentration, MIKI67 mutations and hyper-progressive disease related gene mutations are prognostic markers for camrelizumab and apatinib combined multiline treatment in advanced NSCLC. Front. Oncol., 2020, 10, 1706.
[http://dx.doi.org/10.3389/fonc.2020.01706] [PMID: 33014846]

Yao, J.; Wang, Z.; Sheng, J.; Wang, H.; You, L.; Zhu, X.; Pan, H.; Han, W. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study. Int. Immunopharmacol., 2020, 89(Pt A), 107033.
[http://dx.doi.org/10.1016/j.intimp.2020.107033]

Jin, Y.; Weng, Y.M.; Wei, J.Y.; Peng, M. Clinical efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in the treatment of advanced non-small cell lung] cancer. J. Oncol., 2021, 27(9), 6.

Yang, S.; Zhang, W.; Chen, Q.; Guo, Q. Clinical investigation of the efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy: A retrospective study. Cancer Manag. Res., 2020, 12, 10333-10340.
[http://dx.doi.org/10.2147/CMAR.S280096] [PMID: 33116888]

Xiong, Q.; Qin, B.; Xin, L.; Yang, B.; Song, Q.; Wang, Y.; Zhang, S.; Hu, Y. Real-world efficacy and safety of anlotinib with and without immunotherapy in advanced non-small cell lung cancer. Front. Oncol., 2021, 11, 659380.
[http://dx.doi.org/10.3389/fonc.2021.659380] [PMID: 34395243]

Dhiman, A.; Sharma, R.; Singh, R.K. Target-based anticancer indole derivatives and insight into structure‒activity relationship: A mechanistic review update (2018–2021). Acta Pharm. Sin. B, 2022, 12(7), 3006-3027.
[http://dx.doi.org/10.1016/j.apsb.2022.03.021] [PMID: 35865090]

Sethi, N.S.; Prasad, D.N.; Singh, R.K. Synthesis, Anticancer, and Antibacterial Studies of Benzylidene Bearing 5-substituted and 3,5-disubstituted-2,4-Thiazolidinedione Derivatives. Med. Chem., 2021, 17(4), 369-379.
[http://dx.doi.org/10.2174/1573406416666200512073640] [PMID: 32394843]

Singh, R.K. Key heterocyclic cores for smart anticancer drug–design Part II; Bentham Science Publishers: Sharjah, 2022.
[http://dx.doi.org/10.2174/97898150400741220101]

Singh, R.K.; Kumar, S.; Prasad, D.N.; Bhardwaj, T.R. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives. Eur. J. Med. Chem., 2018, 151, 401-433.
[http://dx.doi.org/10.1016/j.ejmech.2018.04.001] [PMID: 29649739]

Felip Font, E.; Gettinger, S.N.; Burgio, M.A.; Antonia, S.J.; Holgado, E.; Spigel, D.R.; Arrieta, O.; Domine Gomez, M.; Aren Frontera, O.; Brahmer, J.; Chow, L.Q.; Crinò, L.; Butts, C.; Coudert, B.; Horn, L.; Steins, M.; Geese, W.J.; Li, A.; Healey, D.; Vokes, E.E. Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 2017, 28, v462.
[http://dx.doi.org/10.1093/annonc/mdx380.004]

ASCO annual meeting. Pembrolizumab vs. platinum-based chemotherapy as first-line therapy for advanced/metastatic NSCLC with a PD-L1 TPS≥ 1 %: Open-label, phase 3 KEYNOTE-042 study. 2018. Available From: https://meetinglibrary.asco.org/browse-meetings/2018%20ASCO%20Annual%20Meeting

Rittmeyer, A.; Barlesi, F.; Waterkamp, D.; Park, K.; Ciardiello, F.; von Pawel, J.; Gadgeel, S.M.; Hida, T.; Kowalski, D.M.; Dols, M.C.; Cortinovis, D.L.; Leach, J.; Polikoff, J.; Barrios, C.; Kabbinavar, F.; Frontera, O.A.; De Marinis, F.; Turna, H.; Lee, J.S.; Ballinger, M.; Kowanetz, M.; He, P.; Chen, D.S.; Sandler, A.; Gandara, D.R. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017, 389(10066), 255-265.
[http://dx.doi.org/10.1016/S0140-6736(16)32517-X] [PMID: 27979383]

Yi, M.; Jiao, D.; Qin, S.; Chu, Q.; Wu, K.; Li, A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol. Cancer, 2019, 18(1), 60.
[http://dx.doi.org/10.1186/s12943-019-0974-6] [PMID: 30925919]

Shi, S.; Wang, R.; Chen, Y.; Song, H.; Chen, L.; Huang, G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One, 2013, 8(6), e65757.
[http://dx.doi.org/10.1371/journal.pone.0065757] [PMID: 23799045]

Han, Y.; Liu, D.; Li, L. PD-1/PD-L1 pathway: Current researches in cancer. Am. J. Cancer Res., 2020, 10(3), 727-742.
[PMID: 32266087]

Liu, J.; Chen, Z.; Li, Y.; Zhao, W.; Wu, J.; Zhang, Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front. Pharmacol., 2021, 12, 731798.
[http://dx.doi.org/10.3389/fphar.2021.731798] [PMID: 34539412]

Goel, S.; Duda, D.G.; Xu, L.; Munn, L.L.; Boucher, Y.; Fukumura, D.; Jain, R.K. Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev., 2011, 91(3), 1071-1121.
[http://dx.doi.org/10.1152/physrev.00038.2010] [PMID: 21742796]

Wu, J.; Tang, Y.; Liang, X. Targeting VEGF pathway to normalize the vasculature: An emerging insight in cancer therapy. OncoTargets Ther., 2018, 11, 6901-6909.
[http://dx.doi.org/10.2147/OTT.S172042] [PMID: 30410348]

Allen, E.; Jabouille, A.; Rivera, L.B.; Lodewijckx, I.; Missiaen, R.; Steri, V.; Feyen, K.; Tawney, J.; Hanahan, D.; Michael, I.P.; Bergers, G. Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation. Sci. Transl. Med., 2017, 9(385), eaak9679.
[http://dx.doi.org/10.1126/scitranslmed.aak9679] [PMID: 28404866]

Han, B.; Chu, T.; Zhong, R.; Zhong, H.; Zhang, B.; Zhang, W.; Shi, C.; Qian, J.; Han, Y. P1. 04-02 efficacy and safety of sintilimab with anlotinib as first-line therapy for advanced non-small cell lung cancer (NSCLC). J. Thorac. Oncol., 2019, 14(10), S439.
[http://dx.doi.org/10.1016/j.jtho.2019.08.905]